Solid Biosciences (SLDB) Total Liabilities (2017 - 2024)
Solid Biosciences (SLDB) has disclosed Total Liabilities for 8 consecutive years, with $44.8 million as the latest value for Q3 2024.
- Quarterly Total Liabilities rose 10.99% to $44.8 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $44.8 million through Sep 2024, up 10.99% year-over-year, with the annual reading at $38.5 million for FY2023, 20.85% down from the prior year.
- Total Liabilities hit $44.8 million in Q3 2024 for Solid Biosciences, up from $37.7 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $48.6 million in Q4 2022 to a low of $17.2 million in Q2 2020.
- Historically, Total Liabilities has averaged $34.0 million across 5 years, with a median of $38.0 million in 2024.
- Biggest five-year swings in Total Liabilities: plummeted 38.16% in 2021 and later skyrocketed 107.76% in 2023.
- Year by year, Total Liabilities stood at $39.1 million in 2020, then tumbled by 38.16% to $24.2 million in 2021, then surged by 101.03% to $48.6 million in 2022, then fell by 20.85% to $38.5 million in 2023, then rose by 16.5% to $44.8 million in 2024.
- Business Quant data shows Total Liabilities for SLDB at $44.8 million in Q3 2024, $37.7 million in Q2 2024, and $38.0 million in Q1 2024.